Search Results

By AJAY PRAKASH, MD, PhD, and EMIL LOU, MD, PhD, FACP, FASCO  / June 10, 2026

Daraxonrasib in KRAS-Mutant Pancreatic Cancer: A First Step in Shifting the Paradigm of Treatment

Wolpin and colleagues have demonstrated in the global randomized Phase III RASolute 302 trial that daraxonrasib, an oral RAS(ON) inhibitor, nearly doubles median overall survival in previously treated metastatic pancreatic ductal adenocarcinoma, producing a median overall survival of 13.2 months...